New Zealand markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.02+0.30 (+0.64%)
At close: 04:00PM EST
46.50 -0.52 (-1.11%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close46.72
Bid46.76 x 900
Ask46.60 x 1100
Day's range46.60 - 47.15
52-week range42.63 - 57.82
Avg. volume2,054,361
Market cap117.953B
Beta (5Y monthly)0.44
PE ratio (TTM)11.87
EPS (TTM)3.96
Earnings dateN/A
Forward dividend & yield1.90 (4.07%)
Ex-dividend date30 May 2023
1y target est62.50
  • Business Wire

    Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

    PARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.

  • Motley Fool

    2 Biotech Stocks You Can Buy and Hold for the Next Decade

    These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

  • Reuters

    UPDATE 2-White House urges RSV immunization makers to meet demand

    Senior Biden administration officials met with the makers of RSV immunizations for children this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the immunizations targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.